Methods |
Multicentre randomised controlled trial. Individual women. Randomisation in blocks of 4. |
Participants |
Inclusion criteria
Exclusion criteria
Women who had indications for Doppler at last 2nd trimester appointment, e.g. medical history of hypertension, diabetes, previous fetal death, IUGR, hypertensive disorder of pregnancy, treatment with beta agonists, insulin‐dependent diabetes.
Women who at their last second trimester appointment had indications for umbilical Doppler.
Women who had undergone an umbilical Doppler before 28 weeks for any reason whatever.
|
Interventions |
Experimental intervention: umbilical Doppler ultrasound
Single assessment at 28‐34 weeks.
Umbilical Doppler US on day of randomisation, immediately after ultrasound scan monitoring fetal growth.
All further tests performed at clinicians’ request according to standard practices in their AN clinics.
N = 2099 with 1950 analysed.
Control/comparison intervention: no Doppler ultrasound
Single estimation between 28‐34 weeks. |
Outcomes |
AN consultations; days of AN hospitalisation; CTG; ultrasound and Doppler tests.
Peri‐ and neonatal deaths; FD; Apgars; neonatal resuscitation; neonatal transfer; birthweight; SGA.
Disorders occurring after randomisation e.g. PIH; pre‐eclampsia, uterine bleeding, oligohydramnios, suspected IUGR, abnormal CTG patterns.
|
Notes |
France 1997 study in previous version of the review (Bricker 2007). Authors did report umbilical cord pH < 7.20 but only on a subsample of women and the groups were not randomised groups. Findings were: Doppler 188 / 757 (24.8%) and no Doppler 181/761 (23.8%). |
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Unclear risk |
“...randomly divided...” Central randomisation in blocks of four. Sequence generation not described. |
Allocation concealment (selection bias) |
Low risk |
“The randomisation procedure using sealed envelopes was standard in each centre and was carried out by the ultrasonographer immediately after verification of the inclusion criteria and performance of the standard ultrasound scan. The envelopes were prepared centrally and were sent to each centre consecutively numbered.” No ‘opaque’ mentioned.
“The randomisation sequence was verified in two ways. After the end of the study every centre was asked to send back the enveloped that had not been used. It was also checked that the envelopes were used in ascending order.”
Blocks of 4 means that the sequence may have been predicted for at least 1/4 of women. However, with central randomisation and sealed envelopes there is no risk of bias.
|
Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
Blinding not possible. |
Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
Blinding not possible. |
Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
Describe any loss of participants to follow‐up at each data collection point:
Describe any exclusion of participants after randomisation:
Was the analysis ITT? If not has the data been able to be re‐included?
|
Selective reporting (reporting bias) |
Unclear risk |
We have not assessed the trial protocol. |
Other bias |
Low risk |
There appear to be no other biases. |